CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...
Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...
BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback